<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR20">
 <label>20.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Dummer</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Duvic</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Scarisbrick</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Olsen</surname>
    <given-names>EA</given-names>
   </name>
   <name>
    <surname>Rozati</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Eggmann</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Goldinger</surname>
    <given-names>SM</given-names>
   </name>
   <name>
    <surname>Hutchinson</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Geskin</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Illidge</surname>
    <given-names>TM</given-names>
   </name>
   <name>
    <surname>Giuliano</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>YH</given-names>
   </name>
  </person-group>
  <article-title>Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (mycosis fungoides and SÃ©zary syndrome)</article-title>
  <source>Ann Oncol</source>
  <year>2014</year>
  <volume>25</volume>
  <fpage>1807</fpage>
  <lpage>1812</lpage>
  <pub-id pub-id-type="doi">10.1093/annonc/mdu231</pub-id>
  <pub-id pub-id-type="pmid">24948692</pub-id>
 </element-citation>
</ref>
